Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

The Gardasil franchise, which includes vaccines for human papillomavirus (HPV), continues to be a major revenue driver for the company. Recent developments in Merck's pipeline have drawn ...

Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant.

The Gardasil franchise, which includes vaccines for human papillomavirus (HPV), continues to be a major revenue driver for the company. Recent developments in Merck's pipeline have drawn considerable ...

Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

Cramer’s previous comments about the firm have appreciated its GARDASIL drug. Like other healthcare companies, Merck & Co., Inc. (NYSE:MRK) has also struggled due to troubles in China.